APA

Hangalapura B. N., Oosterhoff D., Gupta T., de Groot J., Wijnands P. G. J. T. B., van Beusechem V. W., den Haan J., Tüting T., van den Eertwegh A. J. M., Curiel D. T., Scheper R. J. & de Gruijl T. D. (20110616). Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. : Vaccine.

Chicago

Hangalapura Basav N, Oosterhoff Dinja, Gupta Tarun, de Groot Jan, Wijnands Pepijn G J T B, van Beusechem Victor W, den Haan Joke, Tüting Thomas, van den Eertwegh Alfons J M, Curiel David T, Scheper Rik J and de Gruijl Tanja D. 20110616. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. : Vaccine.

Harvard

Hangalapura B. N., Oosterhoff D., Gupta T., de Groot J., Wijnands P. G. J. T. B., van Beusechem V. W., den Haan J., Tüting T., van den Eertwegh A. J. M., Curiel D. T., Scheper R. J. and de Gruijl T. D. (20110616). Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. : Vaccine.

MLA

Hangalapura Basav N, Oosterhoff Dinja, Gupta Tarun, de Groot Jan, Wijnands Pepijn G J T B, van Beusechem Victor W, den Haan Joke, Tüting Thomas, van den Eertwegh Alfons J M, Curiel David T, Scheper Rik J and de Gruijl Tanja D. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. : Vaccine. 20110616.